OncoMatch/Leukemia — Acute Myeloid (AML)/KMT2A (MLL)
Leukemia — Acute Myeloid (AML)KMT2A (MLL) Clinical Trials
KMT2A (MLL) rearrangements define a high-risk AML subgroup occurring in ~10% of cases and create oncogenic fusion proteins amenable to menin inhibitor therapy. Revumenib received FDA approval for relapsed/refractory KMT2A-rearranged acute leukemia in 2024. Trials investigate menin inhibitors alone and in combination with venetoclax, HMA/venetoclax, or chemotherapy for newly diagnosed and relapsed disease.
Top recruiting KMT2A (MLL) Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Janssen Research & Development, LLC
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Peking University People's Hospital
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC